Company: MLTX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001821586-25-000022
Chunk: 25

Company: MoonLake Immunotherapeutics
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
 with benefits in the event of death, disability, retirement, or termination of employment. 

20

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025(Unaudited)

Components of Net Periodic Benefit Cost under the Plan(in thousands)Three Months Ended September 30, 2025Three Months Ended September 30, 2024Nine Months Ended September 30, 2025Nine Months Ended September 30, 2024Service cost$86$71$246$210Interest cost982425Expected return on plan assets(21)(15)(60)(45)Amortization of unrecognized loss3398Prior service credit recognized in current year(3)(3)(8)(8)Net periodic benefit cost$74$64$211$190The components of net periodic benefit cost other than the service cost component are included in general and administrative expense in the Company's condensed consolidated statements of operations and comprehensive loss.Employer Contributions under the PlanFor the nine months ended September 30, 2025, contributions of $238 thousand (CHF 200 thousand) were made to the Plan. The Company presently anticipates contributing an additional estimated amount of $79 thousand (CHF 67 thousand) to fund the Plan in 2025 for a total of $317 thousand (CHF 266 thousand).

21

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025(Unaudited)

Note 12 — Shareholders’ Equity

Class A Ordinary Shares(1)Class C Ordinary Shares(1)Total Number of Ordinary SharesAuthorizedIssued and OutstandingAuthorizedIssued and OutstandingAuthorizedIssued and OutstandingBalance at January 1, 2025500,000,00063,077,431100,000,000841,269600,000,00063,918,700Conversion of Class C Ordinary Shares into Class A Ordinary Shares—111,949—(111,949)——Option exercised and converted under the Employee Stock Option Plan—93,347———93,347Issuance of Restricted Stock Awards under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan—191,526———191,526Balance at March 31, 2025500,000,00063,474,253100,000,000729,320600,000,000